Routine
Notice
Added
Takeda patent for treating immune-related gastrointestinal adverse events
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Detected
April 1st, 2026
Summary
Takeda patent for treating immune-related gastrointestinal adverse events
Source document (simplified)
METHODS OF TREATING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS IN IMMUNE ONCOLOGY TREATMENTS
Publication EP3433275A1 Kind: A1 Mar 25, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
BRAKE, Rachael L., WESTIN, Eric H.
IPC Classifications
C07K 16/28 20060101AFI20260219BHEP A61K 39/00 20060101ALI20260219BHEP A61P 35/00 20060101ALI20260219BHEP A61P 37/06 20060101ALI20260219BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Analysis generated by AI. Source diff and links are from the original.
Classification
Browse Categories
Agriculture & Food Safety
63
AI Regulation
3
Banking & Finance
265
Consumer & Competition
1
Consumer Protection
44
Courts & Legal
359
Data Privacy & Cybersecurity
74
Defense & National Security
52
Education
20
Energy
107
Environment
85
Government & Legislation
324
Healthcare
136
Housing
16
Immigration
9
Insurance
58
Labor & Employment
113
Legal & Courts
1
Pharma & Drug Safety
103
Securities & Markets
104
Tax
65
Tax & Revenue
1
Telecom & Technology
47
Trade & Sanctions
124
Transportation
57
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.